Assessment Status | Awaiting HTA submission from Applicant |
HTA ID | 22042 |
Drug | Pembrolizumab |
Brand | Keytruda® |
Indication | Is indicated for the adjuvant treatment of adults and adolescent (≥12 years) with stage IIB or IIC melanoma following complete resection. |
Assessment Process | |
Rapid review commissioned | 22/06/2022 |
Rapid review completed | 14/07/2022 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 27/07/2022 |
Pre-submission consultation with Applicant | 15/11/2022 |